Mirabegron(also known as Myrbetriq, YM178) is a potent and selective β3-adrenergic receptor agonist.
Effect of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function.[1]
Mirabegron: a review of recent data and its prospects in the management of overactive bladder.[2]
References:
[1] T.Takasu, et al, J. Pharmacol. Exp. Ther., 2007, 321(2), pp 642-647.